4.2 Article

Clinical and laboratory relevance of JAK2 V617F and BCR-ABL co-existence in Philadelphia positive CML patients

期刊

PAKISTAN JOURNAL OF PHARMACEUTICAL SCIENCES
卷 34, 期 6, 页码 2289-2295

出版社

UNIV KARACHI
DOI: 10.36721/PJPS.2021.34.6.SUP.2289-2295.1

关键词

JAK2 V617F; BCR-ABL and JAK2; chronic myeloid leukaemia; Ph plus leukaemia; MPN and BCR-ABL

资金

  1. Khyber Medical University Publication Fund
  2. Higher Education Commission of Pakistan

向作者/读者索取更多资源

This study found that JAK2-V617F mutation in BCR-ABL positive CML patients is rare, and treatment with TKI may not reduce the burden of JAK2 mutation.
Chronic Myeloid Leukaemia (CML) is characterized by BCR-ABL1 mutation. A number of research studies have published reports of concomitant JAK2-V617F mutation in BCR-ABL positive Chronic Myeloid Leukaemia. This study aims to investigate the frequency of JAK2-V617F mutation in BCR-ABL positive CML cases. After approval from ethical committee, participants were enrolled in the study. A total of 103 samples from CML patients were analysed for the presence of JAK2-V617F mutation using real-time polymerase chain reaction. Patients were monitored for treatment response using real-time quantitative PCR for BCR-ABL1 mutation. Out of 103 samples analysed, 2 patients tested positive for JAK2-V617F mutation. These two patients when treated with standard Tyrosine Kinase Inhibitors (TKI) therapy achieved molecular response and normalized the haemoglobin and white cell counts. However, one patient has sustained thrombocytosis. JAK2 remained positive throughout the treatment course. We could not follow the second patient till the end of the study. JAK2 mutation in BCR-ABL1 mutated CML appears to be rare. Treatment with TKI does not appear to reduce JAK2 mutation burden despite a decrease in BCR-ABL1 copy numbers.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.2
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据